YouTube video by Academy of St Martin in the Fields - Topic

YouTube video by Verlye Mills - Topic

Enlivex (ENLV) terminated a previously announced securities purchase agreement with the Rain Foundation under which Rain had agreed to buy 66,666,667 ordinary shares in a private placement using RAIN tokens, subject to shareholder approval.The company exercised its contractual termination rights, so it will not complete the contemplated private placement and will not seek shareholder approval for the transaction. Enlivex continues to describe itself as a quality longevity company advancing Allocetra™, a clinical-stage immunotherapy for age-related inflammatory conditions such as osteoarthritis, alongside a prediction markets treasury strategy built around the Rain protocol.

Enlivex (Nasdaq: ENLV) reported that, as of July 29, 2026, trading volume on the Rain protocol reached $860 million, representing 622% month-over-month growth in July 2026 versus June 2026. The update relates to Enlivex’s RAIN token-based prediction markets treasury portfolio.According to Enlivex, the Rain Foundation currently projects Rain protocol trading volumes of $1.3 billion in 2027, $12 billion in 2028 and $33 billion in 2029. At those levels, Rain Foundation expects gross fees of $49 million, $436 million and $1.2 billion, and net buy-and-burn allocations of $24 million, $216 million and $600 million, respectively. Enlivex highlights public, unaudited mark-to-market treasury metrics on its website and notes that detailed RAIN token data is available on CoinMarketCap.The company reiterates its dual strategy: advancing Allocetra, a clinical-stage immunotherapy targeting age-related osteoarthritis, while maintaining exposure to the decentralized prediction markets ecosystem through the Rain protocol.

Enlivex (Nasdaq: ENLV) will host a live investor webinar on Thursday, July 30, 2026, at 10:00 AM Eastern Time. Management plans to discuss the rationale and intended use of proceeds for its recently announced private placement, the status and long-term strategy of its Rain protocol-based RAIN treasury, and recent clinical progress of Allocetra™, including its new Regenerative Medicine Advanced Therapy (RMAT) designation from the U.S. FDA for symptomatic knee osteoarthritis in patients aged 64 and older. Investors can register at the provided RedChip webinar link.

Enlivex (Nasdaq: ENLV) entered into a securities purchase agreement with a single institutional investor for a private placement of approximately $400,000,000 of ordinary shares (or equivalents). Shares funded in U.S. dollars, USDT or USD Coin are priced at $5.00, and shares funded in RAIN tokens are priced at $6.00, representing premiums of 17.4% and 40.8%, respectively, to the July 27, 2026 closing price.The investor has currently elected to fund the purchase in RAIN tokens, which may be changed before closing. Enlivex plans to use net proceeds to advance its Rain protocol-based treasury strategy and its clinical-stage immunotherapy Allocetra™, focused on age-related osteoarthritis. The agreement grants Enlivex a discretionary right, for 36 months post-closing, to require the investor to purchase up to an additional $400,000,000 of securities on the same pricing terms. Closing is subject to shareholder approval under Nasdaq Listing Rules 5635(a), 5635(b) and Section 274 of the Israeli Companies Law, after which Enlivex expects to consummate the Transaction.

Enlivex Therapeutics (NASDAQ:ENLV – Get Free Report) was upgraded by research analysts at Zacks Research from a “hold” rating to a “strong-buy” rating in a note issued to investors on Tuesday,Zacks.com reports. Several other brokerages have also recently weighed in on ENLV. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Enlivex Therapeutics in [...]

Enlivex (Nasdaq: ENLV) reported updated treasury metrics tied to its RAIN token holdings. As of July 18, 2026, net asset value (NAV) per ordinary share was $66.16, and the company held 79,550,593,122 RAIN tokens valued at approximately $1.1 billion, based on closing prices on CoinMarketCap.According to Enlivex, these figures are unaudited mark-to-market valuations and are available on its online treasury dashboard. The company couples its clinical-stage Allocetra immunotherapy programs in age-related osteoarthritis with a prediction markets treasury strategy centered on the Rain protocol.

FDA RMAT status for Allocetra in age-related knee osteoarthritis follows Phase I/IIa data and supports a 182-patient Phase IIb trial through 2027.

Phase IIb trial now underway with first U.S. patient dosed.